Treatment Options for Posttraumatic Headache: A Current Review of the Literature
Purpose of Review We evaluate evidence-based treatments for posttraumatic headache (PTH), a secondary headache disorder resulting from traumatic brain injury (TBI), comprising nearly 4% of all symptomatic headache disorders. Utilizing recent publications, we aim to inform clinicians of current treatment methods. Recent Findings There is limited research on PTH treatment. A randomized controlled trial (RCT) of metoclopramide with diphenhydramine for acute PTH found that the treatment group (N = 81) experienced more significant pain improvement than placebo by 1.4 points. For persistent PTH, an open-label study of erenumab (N = 89) found that 28% of participants reported ≥ 50% reduction in moderate-to-severe headache days, but an RCT of fremanezumab showed a non-significant reduction in moderate-to-severe headache days. A randomized crossover study of 40 patients with persistent PTH found that onabotulinum toxin-A decreased cumulative number of headaches/week by 43.3% in the treatment group and increased by 35.1% among placebos. In a study of military veterans with severe posttraumatic stress disorder and persistent/delayed onset PTH (N = 193), patients who received Cognitive Behavioral Therapy reported significant improvements in headache-related disability compared to usual care (aggregate mean HIT-6, -3.4). A transcranial magnetic stimulation (N = 24) study found that 58% of participants with mild TBI-related headache experienced a 50% reduction in headache frequency. Summary New studies indicate promise in improving clinically important outcomes of PTH. However, more research is necessary to determine the optimal treatment and whether combining pharmacologic and nonpharmacologic treatment versus a single modality is more effective..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:28 |
|---|---|
| Enthalten in: |
Current pain and headache reports - 28(2023), 4 vom: 22. Dez., Seite 205-210 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Minen, Mia T. [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| BKL: | |
|---|---|
| Themen: |
Nonpharmacologic treatment |
| Anmerkungen: |
© The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. |
|---|
| doi: |
10.1007/s11916-023-01199-y |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR055148581 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR055148581 | ||
| 003 | DE-627 | ||
| 005 | 20240315064905.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240315s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s11916-023-01199-y |2 doi | |
| 035 | |a (DE-627)SPR055148581 | ||
| 035 | |a (SPR)s11916-023-01199-y-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 084 | |a 44.90 |2 bkl | ||
| 100 | 1 | |a Minen, Mia T. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Treatment Options for Posttraumatic Headache: A Current Review of the Literature |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. | ||
| 520 | |a Purpose of Review We evaluate evidence-based treatments for posttraumatic headache (PTH), a secondary headache disorder resulting from traumatic brain injury (TBI), comprising nearly 4% of all symptomatic headache disorders. Utilizing recent publications, we aim to inform clinicians of current treatment methods. Recent Findings There is limited research on PTH treatment. A randomized controlled trial (RCT) of metoclopramide with diphenhydramine for acute PTH found that the treatment group (N = 81) experienced more significant pain improvement than placebo by 1.4 points. For persistent PTH, an open-label study of erenumab (N = 89) found that 28% of participants reported ≥ 50% reduction in moderate-to-severe headache days, but an RCT of fremanezumab showed a non-significant reduction in moderate-to-severe headache days. A randomized crossover study of 40 patients with persistent PTH found that onabotulinum toxin-A decreased cumulative number of headaches/week by 43.3% in the treatment group and increased by 35.1% among placebos. In a study of military veterans with severe posttraumatic stress disorder and persistent/delayed onset PTH (N = 193), patients who received Cognitive Behavioral Therapy reported significant improvements in headache-related disability compared to usual care (aggregate mean HIT-6, -3.4). A transcranial magnetic stimulation (N = 24) study found that 58% of participants with mild TBI-related headache experienced a 50% reduction in headache frequency. Summary New studies indicate promise in improving clinically important outcomes of PTH. However, more research is necessary to determine the optimal treatment and whether combining pharmacologic and nonpharmacologic treatment versus a single modality is more effective. | ||
| 650 | 4 | |a Posttraumatic headache |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Traumatic brain injury |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Pharmacological treatment |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Nonpharmacologic treatment |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Mahmood, Naoroz |4 aut | |
| 700 | 1 | |a Khan, Fardin |4 aut | |
| 700 | 1 | |a Waire, Erin K. |4 aut | |
| 700 | 1 | |a George, Alexis |4 aut | |
| 700 | 1 | |a Datta, Shae |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current pain and headache reports |d Springer US, 1997 |g 28(2023), 4 vom: 22. Dez., Seite 205-210 |h Online-Ressource |w (DE-627)SPR055090710 |w (DE-600)2094180-8 |w (DE-576)265627125 |x 1534-3081 |7 nnns |
| 773 | 1 | 8 | |g volume:28 |g year:2023 |g number:4 |g day:22 |g month:12 |g pages:205-210 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s11916-023-01199-y |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 936 | b | k | |a 44.90 |j Neurologie |q VZ |
| 951 | |a AR | ||
| 952 | |d 28 |j 2023 |e 4 |b 22 |c 12 |h 205-210 | ||